ライフサイエンスコーパス: A1c

1 A1c reduction was 1.95+/-0.31% from baseline (P<0.0001).

2 A1c was considered controlled if individuals were aged <

3 A1c was lower in ATG/G-CSF-treated subjects at the 6-mon

4 ho received influenza vaccinations and >or=2 A1c tests, to 43% lower for calcium-phosphorus assessmen

5 years; body mass index = 29 +/- 1 kg/m(2) ; A1c = 5.7 +/- 0.1%) were studied on two occasions, with

6 the assay of serum glycated hemoglobin A1c (A1c), hsCRP, d-8-iso, MMP-2, and MMP-9.

7 health habits, reported oral conditions, and A1c and control of diabetes among a subset of youth with

8 ationship between oral hygiene practices and A1c among youth with diabetes is understudied.

9 ft function with improved metabolic control (A1c, fasting glycemia, and metabolic tests) after IAK (1

10 ine albumin, urea, creatinine, electrolytes, A1c, and ambulatory BP at baseline, 24, and 48 wk.

11 n fully adjusted models (for glycohemoglobin A1c, standardized B=-0.10 [-0.15 to -0.05], P<0.001 and

12 In addition, higher glycohemoglobin A1c and fasting plasma glucose were associated with lowe

13 t 2 years, defined as a glycated haemaglobin A1c (HbA1c) concentration of 6.5% or less (</=47.5 mmol/

14 ng renal function, diabetes, and haemoglobin A1c.

15 lesterol, and glycaemic control (haemoglobin A1c) after 2 years.

16 and non-significant increase for haemoglobin A1c (0.04% [-0.04 to 0.13]), p=0.290).

17 d type 2 diabetes, mean glycated haemoglobin A1c (HbA1c) concentration of 67 mmol/mol (8.3%), and ris

18 outcome was a change in glycated haemoglobin A1c (HbA1c) from baseline to week 26, with a 0.4% non-in

19 r with type 2 diabetes, glycated haemoglobin A1c (HbA1c) of 7.0% or more, receiving metformin, sulfon

20 ith type 2 diabetes and glycated haemoglobin A1c (HbA1c) of 7.0-9.5% on stable metformin were randoml

21 Mean glycated haemoglobin A1c concentrations were also higher in the fasting and 2

22 ile, glucose tolerance, glycated haemoglobin A1c, salivary cortisol, sitting height, and head circumf

23 quately controlled (glycosylated haemoglobin A1c [HbA1c] >/=7.0% to </=10.0%) patients with type 2 di

24 lucose, 2-h glucose and insulin, haemoglobin A1c, high-density lipoprotein or blood pressure.

25 ting hyperglycaemia and lowering haemoglobin A1c levels than Exendin-4, suggesting that GLP-1R G-prot

26 +/- 0.043), ferritin (-0.212 +/- 0.075), Hb A1c (-0.052 +/- 0.015), and fasting insulin (-0.119 +/-

27 tin, fasting insulin, and hemoglobin A1c (Hb A1c).

28 lasma CRP, ferritin, fasting insulin, and Hb A1c and lower adiponectin after adjustment for demograph

29 rse correlation between PMCA strength and Hb A1c content, indicating that PMCA activity declines mono

30 t (P = 0.1) after adjustment for baseline Hb A1c and concurrent insulin dose.

31 ntration, body mass index (BMI), baseline Hb A1c, and concurrent insulin dose.

32 r regression models adjusted for baseline Hb A1c, sociodemographic variables, diabetes-related variab

33 cant proportion of associations with CRP, Hb A1c, and fasting insulin (P-contribution </= 0.02 for al

34 +/- 0.5 mg/dL), PI (-1.52 +/- 0.6 mg/dL), Hb A1c (-0.02 +/- 0.0%), and HOMA-IR (-0.04 +/- 0.0) after

35 dL for PG, and -0.01% (-0.02%, 0.00%) for Hb A1c.

36 ated with subsequent glycated hemoglobin (Hb A1c) concentrations during intensive therapy for type 1

37 Improved glycated hemoglobin (Hb A1c) delays the progression of microvascular and macrova

38 stload insulin (PI), glycated hemoglobin (Hb A1c), and homeostasis model assessment of insulin resist

39 Glycated hemoglobin, Hb A1c, was used as a reliable age marker for normal RBCs.

40 r carbohydrate was associated with higher Hb A1c concentrations (P = 0.01); this relation remained si

41 l fat intakes were associated with higher Hb A1c concentrations at year 5.

42 h-Na(+), low-density RBCs had the highest Hb A1c levels, suggesting it represents a late homeostatic

43 gression models tested the association of Hb A1c at year 5 with macronutrient composition and were ad

44 A total of 9.3% of participants had poor Hb A1c (value >/=9.5%) at baseline, which increased to 18.3

45 001, P = 0.003) associated with follow-up Hb A1c after adjustment for confounders.

46 ntly negatively associated with follow-up Hb A1c after adjustment for confounders.

47 utritional factors may be associated with Hb A1c during early stages of disease progression in youth

48 associations of nutritional factors with Hb A1c in youth with T1D.

49 d for direct detection of hemoglobin A1c (Hb(A1c)), a potent biomarker for diabetes diagnosis and pro

50 The polymer allowed Hb(A1c) selectively bound to its surface via forming the ci

51 edox current of PAPBA decreased due to an Hb(A1c) binding-induced ion flux blocking mechanism, which

52 method for developing an electrochemical Hb(A1c) biosensor and can be extended to other label-free,

53 s a linear dependence on the logarithm of Hb(A1c) concentration ranging from 0.975 to 156 muM.

54 Voltammetric analyses showed that Hb(A1c) binding decreased the redox current of PAPBA; howev

55 The Hb(A1c) assay also showed high selectivity against ascorbic

56 Assay with Hb(A1c) by differential pulse voltammetry (DPV) indicates t

57 outcomes included changes in hemoglobin (Hb) A1c (primary outcome), fasting plasma glucose (FPG), ser

58 type 2 diabetes (mean +/- SD hemoglobin (Hb)A1c level: 7.3% +/- 0.94%) and periodontal disease were

59 Hemoglobin A1c (HbA1c) and fasting blood glucose levels (FBGLs) wer

60 Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose c

61 Hemoglobin A1c (HbA1c) levels are known to be consistently higher i

62 Hemoglobin A1c (HbA1c) levels were also recorded.

63 Hemoglobin A1c (HbA1c) reflects glycemia over 2-3 months and is the

64 Hemoglobin A1c (HbA1c) reflects past glucose concentrations, but th

65 Hemoglobin A1c level was not associated with any MR imaging measure

66 Hemoglobin A1c levels were ordered at all ICU admissions from March

67 Hemoglobin A1c stratified by the presence or absence of SCT was the

68 Hemoglobin A1c thresholds of 5.7% and 6.5% were the least effective

69 Prediabetes (glucose based, 4.0%; hemoglobin A1c based, 15.4%) and diabetes (glucose based, 3.0%; hem

70 nd diabetes (glucose based, 3.0%; hemoglobin A1c based, 2.9%) were less frequent.

71 dL vs 8 +/- 17 mg/dL [P < .001]), hemoglobin A1c levels (26 weeks: 0.1 +/- 0.3% vs 0.3 +/- 0.4% [P <

72 abetes was defined as follows: 1) hemoglobin A1c values ranging from 5.7% to 6.4% or 2) fasting plasm

73 e level of 200 mg/dL or higher, a hemoglobin A1c (HbA1c) of 6.5% or higher, or diabetes treatment.

74 ears, the harms associated with a hemoglobin A1c (HbA1c) target lower than 7.5% or higher than 9% are

75 A hemoglobin A1c level less than 7% based on individualized assessmen

76 Prediabetes was defined as a hemoglobin A1c level of 5.7% to 6.4%, an FPG level of 100 mg/dL to

77 ot previously diagnosed, by (1) a hemoglobin A1c level of 6.5% or greater or a fasting plasma glucose

78 t (55% effectiveness; $498), or a hemoglobin A1c threshold of 5.5% (45% effectiveness; $763).

79 1), homocysteine, lipoprotein(a), hemoglobin A1c, creatinine, and conventional lipid levels.

80 ectively; 26.7% met combined ABC (hemoglobin A1c, BP, and LDL cholesterol) targets, and 21.3% met com

81 ticipants with diabetes achieving hemoglobin A1c levels less than 6.5% or fasting plasma glucose valu

82 portion of participants achieving hemoglobin A1c levels less than 7%.

83 After adjustment for sex, age, hemoglobin A1c level, and retinopathy level at DCCT baseline, the f

84 esented 41.0% of patients with an hemoglobin A1c > 6.5% and 9.3% of all ICU patients.

85 A total of 15,737 patients had an hemoglobin A1c and medical record evaluable for the history of diab

86 In a meta-analysis, hemoglobin A1c level decreased by 0.4% (95% CI, 0.1% to 0.7%) (n =

87 >/=7.0 mmol/L [>/=126 mg/dL]) and hemoglobin A1c (>/=6.5%) in persons without diagnosed diabetes.

88 adiponectin, fasting insulin, and hemoglobin A1c (Hb A1c).

89 n levels, insulin resistance, and hemoglobin A1c (HbA1c) levels in first-episode antipsychotic-naive

90 mmol/L or less (</=225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% who were treated for

91 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels were recorded.

92 Besides lowering glucose and hemoglobin A1c (HbA1c) levels, drug treatment also significantly re

93 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels, periodontal parameters (plaque index

94 ividuals with type 1 diabetes and hemoglobin A1c (HbA1c) of at least 7.5% (58 mmol/mol) treated with

95 by height in meters squared) and hemoglobin A1c (HbA1c) was greater than or equal to 6.5%.

96 oring of blood glucose (SMBG) and hemoglobin A1c (HbA1c).

97 glucose, insulin, proinsulin and hemoglobin A1c (HbA1c).

98 mg/dL; 95% CI=-39.2 to -1.3), and hemoglobin A1c level (-0.07%; 95% CI=-0.14 to -0.004).

99 itial macrophage infiltration and hemoglobin A1c level and inversely with estimated glomerular filtra

100 ian of 14 months (IQR, 5-30), and hemoglobin A1c level was 8.1% (IQR, 7.2%-9.9%).

101 (SD) age was 47.3 (6.4) years and hemoglobin A1c level, 7.9% (2.0%).

102 association between DNT score and hemoglobin A1c level.

103 inogen activator inhibitor-1, and hemoglobin A1c level.

104 blood pressure, cholesterol, and hemoglobin A1c levels and treatment and control rates in 1154 self-

105 triglyceride, blood glucose, and hemoglobin A1c levels sharply decreased during the first 2 years af

106 dex, duration posttransplant, and hemoglobin A1c levels were similar between groups.

107 or CVD, inflammatory markers, and hemoglobin A1c levels).

108 ction Questionnaire 25 scores and hemoglobin A1c levels.

109 s determined by blood glucose and hemoglobin A1c levels.

110 er measure): eye examinations and hemoglobin A1c testing for patients with diabetes, chlamydia screen

111 ficacy, medication adherence, and hemoglobin A1c values.

112 0.27) than the control group, and hemoglobin A1c was on average 0.38% lower in the treatment group th

113 ons in fasting glucose levels and hemoglobin A1c were greater after distal gastric bypass.

114 tal body fat mass, VAT, SSAT, and hemoglobin A1c were reduced comparably in both intervention groups.

115 Associations of BP and hemoglobin A1c with change in eGFR were strongest for eGFR(Cys) and

116 ssment of insulin resistance, and hemoglobin A1c) compared with fast ethanol metabolizers (persons ho

117 olesterol, smoking cessation, and hemoglobin A1c.

118 ed to body mass index (10.1%) and hemoglobin A1c/diabetes (8.9%), whereas homocysteine and creatinine

119 Unfortunately, tests such as hemoglobin A1c (HbA1c)/fasting plasma glucose (FPG) alone fail to d

120 Diabetes was defined as hemoglobin A1c greater than 6.5% or use of glucose-lowering medicat

121 Diabetes was defined as hemoglobin A1c level of >/=6.5%, use of diabetic medication, or a p

122 sures of diabetes status (such as hemoglobin A1c levels), and quality of life.

123 osity, stable adiposity, baseline hemoglobin A1c (HbA1c) > 5.05%, HbA1c < 4.92%] and assayed using GC

124 The association of baseline hemoglobin A1c (HbA1c) at the time of percutaneous coronary interve

125 tus and glycemic status (baseline hemoglobin A1c [HbA1c]: < 6.0% [< 42 mmol/mol], 6.0%-6.4% [42-47 mm

126 aded inverse relationship between Hemoglobin A1c and SVR rate (P = .0482).

127 sion making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment plans, outpa

128 ng plasma glucose (FPG) and blood hemoglobin A1c (HbA1c) than individuals of other genotypes.

129 ignificantly associated with BMI, hemoglobin A1c, systolic blood pressure, total cholesterol, LDL cho

130 nd control of diabetes defined by hemoglobin A1c (HbA1c) levels are important for health care policy

131 risk of CVD (28.7%), followed by hemoglobin A1c/diabetes (25.3%), inflammatory/hemostatic factors (5

132 l examination and a point-of-care hemoglobin A1c (HbA1c) test.

133 -density lipoprotein cholesterol, hemoglobin A1c, albuminuria, glomerular filtration rate, smoking, a

134 istics; medications; cholesterol, hemoglobin A1c, and serum creatinine levels; blood pressure; body m

135 od pressure, waist circumference, hemoglobin A1c (HbA1c), insulin resistance, triglycerides, HDL chol

136 betes with poor glycemic control (hemoglobin A1c > 9%) showed a nonstatistically significant decrease

137 Intensive glucose control (hemoglobin A1c [HbA1c] level of 7.0) versus moderate glucose contro

138 haracteristics, glycemic control (hemoglobin A1c [HbA1c]), and presence of diabetic complications wer

139 independent of diabetes control (hemoglobin A1c, blood pressure, and lipid levels), presenting visua

140 Baseline descriptive data, hemoglobin A1c (%) level, time since diagnosis of T1DM (months), an

141 -up interval, insulin dependence, hemoglobin A1c, and total number of lasers spots.

142 and uncontrolled known diabetes (hemoglobin A1c > 6.5%, with documented history of diabetes).

143 rized as having unknown diabetes (hemoglobin A1c > 6.5%, without history of diabetes), no diabetes (h

144 etes), controlled known diabetes (hemoglobin A1c < 6.5%, with documented history of diabetes), and un

145 istory of diabetes), no diabetes (hemoglobin A1c < 6.5%, without history of diabetes), controlled kno

146 mally controlled type 1 diabetes (hemoglobin A1c [HbA1c] >8.0%) were recruited from the Diabetes Cent

147 participants developed diabetes (hemoglobin A1c level >/=6.5%) during the trial: 7 in the high-fiber

148 100 by age, duration of diabetes, hemoglobin A1c (HbA1c), body mass index (BMI), best-corrected visua

149 and, for patients with diabetes, hemoglobin A1c), influenza vaccination, and by at least one outpati

150 cose level of at least 200 mg/dL, hemoglobin A1c concentration of at least 6.5% of total hemoglobin,

151 diabetes type, diabetes duration, hemoglobin A1c (HbA1c) levels, and baseline DR severity.

152 duration of diabetes and elevated hemoglobin A1c (HbA1c) with risk of stroke among diabetic patients

153 er medical history or an elevated hemoglobin A1c in the ICU.

154 agnosed adults have less elevated hemoglobin A1c levels, less lipid treatment and worse control, and

155 ease monitoring (eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol tes

156 ease monitoring (eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol tes

157 tes and established risk factors (hemoglobin A1c level, body mass index, waist-height ratio, and mean

158 primary renal allograft failure, hemoglobin A1c (HbA1c) or fasting C-peptide level at retransplant a

159 d (GCB) could be used to test for hemoglobin A1c (HbA1c) during periodontal visits.

160 The goal for hemoglobin A1c level should be based on individualized assessment o

161 6) years for age, 7.8% (1.9%) for hemoglobin A1c level, and 171.3 (72.5) mg/dL for fasting plasma glu

162 Blood samples were assessed for hemoglobin A1c, fasting blood glucose, and serum lipids.

163 tions defined by fasting glucose, hemoglobin A1c, and medication use obtained during an in-person vis

164 t for the assay of serum glycated hemoglobin A1c (A1c), hsCRP, d-8-iso, MMP-2, and MMP-9.

165 200 mg/dl (11.1 mmol/l), glycated hemoglobin A1c (HbA1c) >6.5%, self-reported physician-diagnosed dia

166 CIs) were calculated for glycated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), total cholest

167 ur CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, and cases were tested

168 thnicity, net worth, and glycated hemoglobin A1c fraction (HbA1c).

169 or duration of diabetes, glycated hemoglobin A1c level, and other factors, we found that neither the

170 Glycated hemoglobin A1c levels improved to 7.0% [6.4%-7.5%] in the DJBL grou

171 The mean (SD) glycated hemoglobin A1c of the 50 patients (26 men and 24 women; 35 Chinese;

172 waist circumference with glycated hemoglobin A1c reduction is likely due to selection bias.

173 significant predictor of glycated hemoglobin A1c reduction was waist circumference, lower baseline wa

174 , whereas guidelines for glycated hemoglobin A1c testing for type 2 diabetes mellitus could be improv

175 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin were abstracted by 2 i

176 n histories of patients' glycated hemoglobin A1c, hypertension, hyperlipidemia, smoking, and renal im

177 rating scale), level of glycated hemoglobin A1c, level of C-reactive protein, body mass index, and p

178 The percentage of glycosylated hemoglobin A1c (%GHbA1c) in human whole blood indicates the average

179 ds to detect tHb and glycosylated hemoglobin A1c (GHbA1c) in human whole blood without sample pretrea

180 Research targeting glycosylated hemoglobin A1c (HbA1c) to <6.5% to prevent coronary heart disease (

181 Elevated levels of glycosylated hemoglobin A1c (OR, 1.47; 95% CI, 1.26-1.71 for each 1%; P < .001)

182 , diabetes duration, glycosylated hemoglobin A1c, and fasting C-peptide.

183 teopontin, and serum glycosylated hemoglobin A1c, insulin, and glucose were analyzed in 220 participa

184 f diabetes mellitus, glycosylated hemoglobin A1c, statin use, and end-stage renal disease.

185 ulin resistance, and glycosylated hemoglobin A1c.

186 G) level of 126 mg/dL or greater (hemoglobin A1c or FPG definition) or (2) additionally including 2-h

187 G) level of 200 mg/dL or greater (hemoglobin A1c, FPG, or 2-hour PG definition).

188 ly injections of insulin, and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9% (mean, 8.5%).

189 daily insulin injections and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9%.

190 cases had a glycated hemoglobin (hemoglobin A1c) test as one of the pair of events identifying diabe

191 athy group and patients with high hemoglobin A1c (HbA1c) values (>/= 6.5%, >/= 48 mmol/mol) exerted s

192 high depression ratings and high hemoglobin A1c levels had the lowest mean FA values in the right AL

193 ith poor glucose control and high hemoglobin A1c levels.

194 e exists as to whether the higher hemoglobin A1c (HbA1c) levels observed in black persons than in whi

195 7-1.11 per year increase), higher hemoglobin A1c (OR, 1.23; 95% CI, 1.13-1.34 per percent increase),

196 Patients with higher hemoglobin A1c levels (OR, 1.19 per unit change; 95% CI, 1.13-1.25

197 Insulin can help achieve ideal hemoglobin A1c goals for patients with type 2 diabetes.

198 diabetes (from 12.7% to 47.6% if hemoglobin A1c level>/=9%), use of antipsychotics (from 12.7% to 31

199 Pioglitazone treatment improved hemoglobin A1c (HbA1c), plasma glucose, insulin levels, and homeost

200 Primary outcome was change in hemoglobin A1c (HbA1c) from baseline to 12-month follow-up, and equ

201 e primary end point was change in hemoglobin A1c (HbA1c) from baseline to week 26.

202 er metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry.

203 ssociated with acute decreases in hemoglobin A1c (HbA1c).

204 the RSG group (mean difference in hemoglobin A1c -0.65%, p < 0.0001).

205 ic control (>/= 0.4% reduction in hemoglobin A1c [HbA1c]), whereas most diabetes self-management educ

206 istically significant declines in hemoglobin A1c control.

207 econd example concerns changes in hemoglobin A1c in a nonrandomized study.

208 Change in hemoglobin A1c level (primary outcome) and safety and efficacy meas

209 es, there was a small decrease in hemoglobin A1c level from baseline that favored subcutaneous insuli

210 lfonylureas (absolute decrease in hemoglobin A1c level of about 1 percentage point).

211 ulted in a remarkable decrease in hemoglobin A1c levels (7.4+/-1.9 pre-LVAD versus 6.0+/-1.5 and 6.3+

212 group and had a small increase in hemoglobin A1c levels (between-group difference, -0.2%; 95% CI, -0.

213 e, 0.9-1.43 point improvements in hemoglobin A1c levels) during 1 to 2 years of follow-up than nonsur

214 was associated with a decrease in hemoglobin A1c of approximately 1.0%.

215 n 2006 and 2010, but increases in hemoglobin A1c testing may have contributed to rising diabetes inci

216 Reductions in hemoglobin A1c values were similar across monotherapies and metform

217 tic individuals, a 1% increase in hemoglobin A1c was associated with greater AD signature hypometabol

218 greater weight loss, reduction in hemoglobin A1c, and use of antidiabetic medications, and very impor

219 nificant effects on the change in hemoglobin A1c, glucose, and insulin levels.

220 ated clinical measures, including hemoglobin A1c level and vascular risk factors, and neuropsychologi

221 .6%, and 80.6% met individualized hemoglobin A1c, blood pressure (BP <140/80 mmHg), lipid (low-densit

222 t of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant sh

223 t of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant sh

224 >/= 30 consecutive days, and (iv) hemoglobin A1c >/= 6.5%.

225 , medications, cholesterol level, hemoglobin A1c level, creatinine level, blood pressure, body mass i

226 index, C-reactive protein level, hemoglobin A1c level, phosphorus level, troponin T level, log N-ter

227 ng fasting plasma glucose levels, hemoglobin A1c levels, and duration of diabetes.

228 peptide (in nanomoles per liter), hemoglobin A1c (as a percentage) and insulin dose (U/kg per day) as

229 Lower hemoglobin A1c and BP and regression to AER<300 mg/d were associate

230 reatment is associated with lower hemoglobin A1c in individuals with diabetes, but the relationship b

231 sociated with significantly lower hemoglobin A1c levels (beta = -0.37; 95% CI, -0.72 to -0.01) and a

232 Lower hemoglobin A1c levels (P < 0.01), having insurance (P = 0.01), and

233 ypoglycemic events and maintained hemoglobin A1c (HbA1c) level of </= 6.5%.

234 range, 0.1-16.2 years) and a mean hemoglobin A1c (HbA1c) of 8.6 (range, 5->/=14).

235 Although mean hemoglobin A1c did not change, the proportion of persons with hemog

236 Mean hemoglobin A1c for the population was 7.9+/-1.8%.

237 uartile (score <42%) had a median hemoglobin A1c level of 7.6% (interquartile range, 6.5% to 9.0%) co

238 quartile range 25.5-35.3), median hemoglobin A1c was 6.8 (interquartile range 6.2-7.8), and 34% had e

239 patients with diabetes mellitus (hemoglobin A1c, 10+/-2%) demonstrated reduced overall cell numbers

240 7.0%, 57.9%, 36.0%, and 77.9% met hemoglobin A1c, BP, lipid, and nonsmoking goals, respectively; 22.1

241 nsulin monotherapy and normalizes hemoglobin A1c with far less glucose variability.

242 ic method for direct detection of hemoglobin A1c (Hb(A1c)), a potent biomarker for diabetes diagnosis

243 dual detection and measurement of hemoglobin A1c (HbA1c) and total hemoglobin in the whole blood (wit

244 study is to evaluate the value of hemoglobin A1c (HbA1c) as a screening tool for ketosis in T2DM pati

245 and longitudinal measurements of hemoglobin A1c (HbA1c) level, after adjustment for all significant

246 used to assess concentrations of hemoglobin A1c and C-reactive protein.

247 ofiling, including measurement of hemoglobin A1c and lipid levels and carotid ultrasonography.

248 Measurement of hemoglobin A1c at admission can prospectively identify a population

249 m effect on secondary outcomes of hemoglobin A1c levels, depression, or the Risk Perceptions and Risk

250 y, in diabetics, higher levels of hemoglobin A1c was associated with greater risk for 4-year incident

251 benefits (measured by lowering of hemoglobin A1c) or adverse effects?

252 , individuals with high levels of hemoglobin A1c, and those with longer duration of diabetes.

253 t metformin had similar levels of hemoglobin A1c, cholesterol, and blood pressure.

254 Baseline levels of hemoglobin A1c, inflammatory markers, hemostatic factors, and lipid

255 n, we measured baseline levels of hemoglobin A1c, traditional lipids (total, low-density lipoprotein,

256 included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; al

257 outcome was most recent level of hemoglobin A1c.

258 They had a favorable effect on hemoglobin A1c level (mean difference vs. placebo, -0.66% [95% CI,

259 rediabetes was estimated based on hemoglobin A1c measurements.

260 safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with

261 after CPB from the UDM patients (hemoglobin A1c [HbA1c]=9.0 +/- 0.3), the CDM patients (HbA1c=6.3 +/

262 Diabetic patients (hemoglobin A1c, 6.8 +/- 0.4%) had a higher resting HR (77.0 +/- 12.

263 0.15), and nondiabetic patients (hemoglobin A1c=5.4 +/- 0.12) undergoing coronary artery bypass graf

264 trolled type 2 diabetic patients (hemoglobin A1c=6.5 +/- 0.15), and nondiabetic patients (hemoglobin

265 trolled type 2 diabetic patients (hemoglobin A1c=9.6 +/- 0.25), controlled type 2 diabetic patients (

266 a known determinant of percentage hemoglobin A1c (HbA1c), its variation has been considered insuffici

267 investigate whether preoperative hemoglobin A1c (HbA1c) levels could predict cardiovascular events o

268 Whether preoperative hemoglobin A1c (HbA1c) or postoperative glucose levels are more use

269 Preoperative hemoglobin A1c was not significantly associated with mortality or a

270 weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 m

271 (OR = 1.49; CI, 1.28-1.74), prior hemoglobin A1c test (OR = 1.45; CI, 1.28-1.64), and having a usual

272 h-sensitivity C-reactive protein, hemoglobin A1c, HDL cholesterol, LDL cholesterol, and triglycerides

273 ood pressure, waist to hip ratio, hemoglobin A1c level, and the ratio of apolipoprotein B to apolipop

274 Age, albumin/creatinine ratio, hemoglobin A1c, diabetes, hypertension, and lipid-lowering therapy

275 es of care, including most recent hemoglobin A1c level, systolic blood pressure, serum low-density li

276 nied with a subsequently recorded hemoglobin A1c level<6.0%).

277 Empagliflozin reduced hemoglobin A1c significantly in both groups, despite lower insulin

278 The mean (SD) hemoglobin A1c level was 7.8% (2.4%) (to convert to proportion of t

279 ry isoelectric focusing separated hemoglobin A1c into two subfractions identified as A1c1 and A1c2.

280 tration Decision Support Services hemoglobin A1c (HbA(c)) and serum glucose data.

281 s, myocardial infarction, stroke, hemoglobin A1c (HbA1C) level, treatment failure (rescue treatment o

282 iometric method for measuring the hemoglobin A1c (HbA1c, glycated hemoglobin) concentration, hemoglob

283 ozin, even though, by design, the hemoglobin A1c difference between the randomized groups was margina

284 ence of total diabetes (using the hemoglobin A1c or FPG definition) increased from 9.8% (95% CI, 8.9%

285 ence of total diabetes (using the hemoglobin A1c or FPG definition) was 12.3% (95% CI, 10.8%-14.1%);

286 The hemoglobin A1c target for most patients with type 2 diabetes is 7%

287 ence of total diabetes (using the hemoglobin A1c, FPG, or 2-hour PG definition) was higher among non-

288 unadjusted prevalence (using the hemoglobin A1c, FPG, or 2-hour PG definitions for diabetes and pred

289 elated with DM-related variables (hemoglobin A1c [HbA1c] and fasting glucose) at baseline and with 6-

290 between baseline and time-varying hemoglobin A1c (HbA1c) values and development of community antiinfe

291 sive and standard treatment were: hemoglobin A1c <6.0% and 7.0% to 7.9%, respectively, and in the blo

292 between FA of the left ALIC with hemoglobin A1c in diabetic subjects (DC+DD; P=.016).

293 exception of interleukin 22) with hemoglobin A1c levels.

294 ars; mean BMI was 25.4 +/- 5.2 kg/m(2); mean A1c was 6.5% +/- 1.1%; insulin use was 0.31 +/- 0.22 uni

295 e periodontal disease improved significantly A1c levels but did not result in a statistically signifi

296 ely, two sustained insulin independence with A1c reduction below graft dysfunction criteria.

297 rs with A1c <7.5%; and aged >/=19 years with A1c <7.0%.

298 ars with A1c <8.0%; aged 12 to 18 years with A1c <7.5%; and aged >/=19 years with A1c <7.0%.

299 ears with A1c <8.5%; aged 7 to 11 years with A1c <8.0%; aged 12 to 18 years with A1c <7.5%; and aged

300 led if individuals were aged </=6 years with A1c <8.5%; aged 7 to 11 years with A1c <8.0%; aged 12 to